专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2009114400A1 ES CELL-DERIVED MICE FROM DIPLOID HOST EMBRYO INJECTION 审中-公开
标题翻译： ES细胞衍生的来自DIPLOID HOST EMBRYO注射的小鼠
公开(公告)号：WO2009114400A1
公开(公告)日：2009-09-17
申请号：PCT/US2009/036276
申请日：2009-03-06
申请人： REGENERON PHARMACEUTICALS, INC. , POUEYMIROU, William , DECHIARA, Thomas, M. , AUERBACH, Wojtek , ECONOMIDES, Aris, N. , GALE, Nicholas, W. , FRENDEWEY, David , VALENZUELA, David, M.
发明人： POUEYMIROU, William , DECHIARA, Thomas, M. , AUERBACH, Wojtek , ECONOMIDES, Aris, N. , GALE, Nicholas, W. , FRENDEWEY, David , VALENZUELA, David, M.
IPC分类号： C12N15/85 , C12N15/90 , A61D19/00 , A01K67/027 , C12N5/10 , C12N5/06
CPC分类号： A01K67/0271 , A01K67/0275 , A01K2207/12 , A01K2217/00 , A01K2217/05 , A01K2217/07 , A01K2217/15 , A01K2217/203 , A01K2217/30 , A01K2227/105 , A01K2267/02 , C12N5/16 , C12N15/8509 , C12N15/907 , C12N2510/00 , C12N2517/02
摘要： Genetically modified mice and nucleic acid constructs for making the genetically modified mice are described. A first mouse having a gene encoding an activator (such as a Cre recombinase) operably linked to a developmentally-regulated promoter (such as a Nanog promoter) is provided. A second mouse having a toxic responder gene (such as a gene encoding diphtheria toxin A) is provided, where the toxic gene is expressed only in the presence of an activator. Embryos from a mating of the first and the second mouse are provided as host embryos suitable for generating mice from donor cells introduced into the host embryos. Ablating the ICM of a mouse embryo physically, chemically, or genetically is described, as well as making FO generation mice that are substantially or in full derived from donor cells, employing a host mouse embryo with an ablated or nonproliferating ICM.
摘要翻译：描述了用于制备遗传修饰的小鼠的转基因小鼠和核酸构建体。提供了具有编码与发育调节的启动子（例如Nanog启动子）可操作地连接的活化剂（例如Cre重组酶）的基因的第一只小鼠。提供具有毒性反应基因（例如编码白喉毒素A的基因）的第二只小鼠，其中毒性基因仅在活化剂存在下表达。提供来自第一和第二小鼠交配的胚胎作为宿主胚，适于从引入宿主胚胎的供体细胞产生小鼠。描述了在物理，化学或遗传上消除小鼠胚胎的ICM，以及使用具有消融或非增殖ICM的宿主小鼠胚胎制备基本上或完全衍生自供体细胞的FO代小鼠。

2. 发明申请

WO2016039796A2 TREATMENT OF FIBRODYSPLASIA OSSIFICANS PROGRESSIVA 审中-公开
标题翻译： FIBROSYSPLASIA OSSIFICANS PROGRESSIVA的治疗
公开(公告)号：WO2016039796A2
公开(公告)日：2016-03-17
申请号：PCT/US2015/000100
申请日：2015-09-14
申请人： REGENERON PHARMACEUTICALS, INC.
发明人： HATSELL, Sarah, J. , ECONOMIDES, Aris, N. , IDONE, Vincent, J.
IPC分类号： C07K16/22
CPC分类号： C07K16/18 , A61K38/179 , A61K39/39533 , A61K2039/505 , C07K14/705 , C07K16/22 , C07K16/28 , C07K16/2863 , C07K2317/21 , C07K2317/24 , C07K2317/33 , C07K2319/30
摘要： Methods for treating Fibrodysplasia Ossificans Progressiva (FOP) are provided. Such methods involve administering to a subject having FOP an effective regime of an activin receptor type 2A (ACVR2A) and/or an activin receptor type 2B (ACVR2B) antagonist or an activin receptor type 1 (ACVRl) antagonist. Antagonists include fusion proteins of one or more extracellular domains (ECDs) of ACVR2A, ACVR2B and/or ACVRl and the Fc domain of an immunoglobulin heavy chain, and antibodies against ACVR2A, ACVR2B, ACVRl or Activin A.
摘要翻译：提供治疗纤维发育不良症的方法Progressiva（FOP）。这样的方法包括向具有FOP的受试者施用2A型激活素受体（ACVR2A）和/或2B（ACVR2B）激动素受体拮抗剂或激活素受体1型（ACVR1）拮抗剂的有效方案。拮抗剂包括ACVR2A，ACVR2B和/或ACVR1的一个或多个细胞外结构域（ECD）和免疫球蛋白重链的Fc结构域的融合蛋白，以及针对ACVR2A，ACVR2B，ACVR1或活化素A的抗体。

3. 发明申请

WO2018023014A1 MICE COMPRISING MUTATIONS RESULTING IN EXPRESSION OF C-TRUNCATED FIBRILLIN-1 审中-公开
标题翻译：包含引起C-受体结合的FIBRILLIN-1表达的突变的小鼠
公开(公告)号：WO2018023014A1
公开(公告)日：2018-02-01
申请号：PCT/US2017/044409
申请日：2017-07-28
申请人： REGENERON PHARMACEUTICALS, INC.
发明人： HUNT, Charleen , MASTAITIS, Jason , GONG, Guochun , LAI, Ka-Man Venus , GROMADA, Jesper , ECONOMIDES, Aris, N.
IPC分类号： A01K67/027
摘要： Provided are non-human animals comprising a mutation in the Fbnl gene to model neonatal progeroid syndrome with congenital lipodystrophy (NPSCL). Also provided are methods of making such non-human animal models. The non-human animal models can be used for screening compounds for activity in inhibiting or reducing NPSCL or ameliorating NPSCL- like symptoms or screening compounds for activity potentially harmful in promoting or exacerbating NPSCL as well as to provide insights in to the mechanism of NPSCL and potentially new therapeutic and diagnostic targets.
摘要翻译：提供包含Fbnl基因中的突变的非人动物以模拟具有先天性脂肪代谢障碍（NPSCL）的新生儿原病综合征。还提供了制造这种非人动物模型的方法。非人类动物模型可用于筛选化合物抑制或减少NPSCL或改善NPSCL样症状的活性或筛选化合物的活性，以促进或加剧NPSCL的潜在危害，并提供对NPSCL机制的见解和潜在的新的治疗和诊断目标。

4. 发明申请

WO2002036789A3 METHODS OF MODIFYING EUKARYOTIC CELLS 审中-公开
公开(公告)号：WO2002036789A3
公开(公告)日：2002-05-10
申请号：PCT/US2001/045375
申请日：2001-10-31
申请人： REGENERON PHARMACEUTICALS, INC. , ECONOMIDES, Aris, N. , MURPHY, Andrew, J. , VALENZUELA, David, M. , FRENDEWEY, David , YANCOPOULOS, George, D.
发明人： ECONOMIDES, Aris, N. , MURPHY, Andrew, J. , VALENZUELA, David, M. , FRENDEWEY, David , YANCOPOULOS, George, D.
IPC分类号： C12N15/90
摘要： A method for engineering and utilizing large DNA vectors to target, via homologous recombination, and modify, in any desirable fashion, endogenous genes and chromosomal loci in eukaryotic cells. These large DNA targeting vectors for eukaryotic cells, termed LTVECs, are derived from fragments of cloned genomic DNA larger than those typically used by other approaches intended to perform homologous targeting in eukaryotic cells. Also provided is a rapid and convenient method of detecting eukaryotic cells in which the LTVEC has correctly targeted and modified the desired endogenous genes(s) or chromosomal locus (loci) as well as the use of these cells to generate organisms bearing the genetic modification.

5. 发明申请

WO2011059799A1 MULTIFUNCTIONAL ALLELES 审中-公开
标题翻译：多功能对象
公开(公告)号：WO2011059799A1
公开(公告)日：2011-05-19
申请号：PCT/US2010/054654
申请日：2010-10-29
申请人： REGENERON PHARMACEUTICALS, INC. , ECONOMIDES, Aris, N. , MURPHY, Andrew, J. , LENGYEL, Peter, Matthew , YANG, Peter, H., A.
发明人： ECONOMIDES, Aris, N. , MURPHY, Andrew, J. , LENGYEL, Peter, Matthew , YANG, Peter, H., A.
IPC分类号： C12N15/10 , C12N15/90
CPC分类号： C12N15/907 , A01K2217/15 , A01K2217/20 , C12N9/00 , C12N15/63 , C12N2800/30 , C12N2800/60 , C12N2840/44
摘要： Nucleic acid constructs and methods for rendering modifications to a genome are provided, wherein the modifications comprise null alleles, conditional alleles and null alleles comprising COINs. Multifunctional alleles (MFA) are provided, as well as methods for making them, which afford the ability in a single targeting to introduce an allele that can be used to generate a null allele, a conditional allele, or an allele that is a null allele and that further includes a COIN. MFAs comprise pairs of cognate recombinase recognition sites, an actuating sequence and/or a drug selection cassette, and a nucleotide sequence of interest, and a COIN, wherein upon action of a recombinase a conditional allele with a COIN is formed. In a further embodiment, action of a second recombinase forms an allele that contains only a COIN in sense orientation. In a further embodiment, action by a third recombinase forms an allele that contains only the actuating sequence in sense orientation.
摘要翻译：提供了核酸构建体和用于对基因组进行修饰的方法，其中所述修饰包括无效等位基因，条件等位基因和包含COIN的无效等位基因。提供多功能等位基因（MFA）以及制备它们的方法，其提供单次靶向引入可用于产生无效等位基因，条件等位基因或等位基因的等位基因的能力，其为无效等位基因并且还包括一个COIN。 MFAs包括成对的同源重组酶识别位点，启动序列和/或药物选择盒，以及目标核苷酸序列和COIN，其中在重组酶作用下，形成了具有COIN的条件等位基因。在另一个实施方案中，第二重组酶的作用形成仅包含正义取向的COIN的等位基因。在另一个实施方案中，第三重组酶的作用形成仅含义义方向的致动序列的等位基因。

6. 发明申请

WO2010022120A1 HUMAN ANTIBODIES TO HUMAN RANKL 审中-公开
标题翻译：人类抗体对人类RANKL
公开(公告)号：WO2010022120A1
公开(公告)日：2010-02-25
申请号：PCT/US2009/054262
申请日：2009-08-19
申请人： REGENERON PHARMACEUTICALS, INC. , MARTIN, Joel, H. , ECONOMIDES, Aris, N. , RAZ, Regina
发明人： MARTIN, Joel, H. , ECONOMIDES, Aris, N. , RAZ, Regina
IPC分类号： C07K16/28 , A61P19/00 , A61P35/00
CPC分类号： C07K16/2875 , A61K2039/505 , C07K2317/21
摘要： Isolated human antibodies or antigen-binding fragments thereof, which specifically bind to human RANKL and block hRANKL binding to a RANK receptor, are provided. The antibodies are useful in preventing or treating disorders and/or diseases, which are associated with RANKL/RANK interactions, including bone disorders or cancer.
摘要翻译：提供了特异性结合人RANKL并阻断hRANKL与RANK受体结合的分离的人抗体或其抗原结合片段。所述抗体可用于预防或治疗与RANKL / RANK相互作用（包括骨病或癌症）相关的疾病和/或疾病。

7. 发明申请

WO2003020743A1 METHODS OF EXPRESSING TRANSGENES 审中-公开
标题翻译：表达转基因的方法
公开(公告)号：WO2003020743A1
公开(公告)日：2003-03-13
申请号：PCT/US2002/028240
申请日：2002-09-05
申请人： REGENERON PHARMACEUTICALS, INC. , ECONOMIDES, Aris, N. , DECHIARA, Thomas, M. , GALE, Nicholas, W. , YANCOPOULOS, George, D.
发明人： ECONOMIDES, Aris, N. , DECHIARA, Thomas, M. , GALE, Nicholas, W. , YANCOPOULOS, George, D.
IPC分类号： C07H21/02
CPC分类号： A01K67/0275 , A01K2217/05 , C12N15/907 , C12N2800/30 , C12N2830/001 , C12N2830/008 , C12N2830/30 , C12N2830/32 , C12N2830/85 , C12N2840/20 , C12N2840/203 , C12N2840/44
摘要： The present invention is a novel method of expressing transgenes in vivo by targeting protected transgene cassettes into predetermined loci, including ubiquitously expressed chromosomal loci, such that the activity of an exogenous promoter is maintained. The advantages of this method are that the expression pattern is determined primarily by the nature of the exogenous promoter and, therefore, is not subject to positional effects. The invention also encompasses the DNA targeting vectors, the targeted cells, as well as non-human organisms, especially mice, created from the targeted cells.
摘要翻译：本发明是通过将受保护的转基因盒定向到预定的位点（包括普遍表达的染色体基因座），从而维持外源启动子的活性而在体内表达转基因的新方法。该方法的优点在于表达模式主要由外源启动子的性质决定，因此不受定位效应的影响。本发明还包括从靶细胞产生的DNA靶向载体，靶细胞以及非人生物，特别是小鼠。

8. 发明申请

WO2013138400A1 MULTISPECIFIC ANTIGEN-BINDING MOLECULES AND USES THEREOF 审中-公开
标题翻译：多重抗原结合分子及其用途
公开(公告)号：WO2013138400A1
公开(公告)日：2013-09-19
申请号：PCT/US2013/030636
申请日：2013-03-13
申请人： REGENERON PHARMACEUTICALS, INC.
发明人： PAPADOPOULOS, Nicholas, J. , MURPHY, Andrew, J. , ECONOMIDES, Aris, N. , CYGNAR, Katherine, Diana
IPC分类号： C07K14/705 , C07K16/28
CPC分类号： C07K16/28 , A61P19/08 , A61P35/00 , C07K14/705 , C07K16/1203 , C07K16/22 , C07K16/283 , C07K16/2866 , C07K16/2896 , C07K2317/31 , C07K2317/77
摘要： The present invention provides multispecific antigen-binding molecules and uses thereof. The multispecific antigen-binding molecules comprise a first antigen-binding domain that specifically binds a target molecule, and a second antigen-binding domain that specifically binds an internalizing effector protein. The multispecific antigen-binding molecules of the present invention can, in some embodiments, be bispecific antibodies that are capable of binding both a target molecule and an internalizing effector protein. In certain embodiments of the invention, the simultaneous binding of the target molecule and the internalizing effector protein by the multispecific antigen-binding molecule of the present invention results in the attenuation of the activity of the target molecule to a greater extent than the binding of the target molecule alone. In other embodiments of the invention, the target molecule is a tumor associated antigen, and the simultaneous binding of the tumor associated antigen and the internalizing effector protein by the multispecific antigen-binding molecule of the present invention causes or facilitates the targeted killing of tumor cells.
摘要翻译：本发明提供多特异性抗原结合分子及其用途。多特异性抗原结合分子包含特异性结合靶分子的第一抗原结合结构域和特异性结合内在效应蛋白的第二抗原结合结构域。在一些实施方案中，本发明的多特异性抗原结合分子可以是能够结合靶分子和内化效应蛋白的双特异性抗体。在本发明的某些实施方案中，通过本发明的多特异性抗原结合分子同时结合靶分子和内化效应蛋白导致目标分子的活性比所述靶分子的结合更大程度地减弱靶分子单独。在本发明的其它实施方案中，靶分子是肿瘤相关抗原，并且通过本发明的多特异性抗原结合分子同时结合肿瘤相关抗原和内在效应蛋白导致或促进靶向杀伤肿瘤细胞。

9. 发明申请

WO2005001087A2 METHODS OF MODIFYING GENES IN EUKARYOTIC CELLS 审中-公开
标题翻译：在真核细胞中修饰基因的方法
公开(公告)号：WO2005001087A2
公开(公告)日：2005-01-06
申请号：PCT/US2004/018964
申请日：2004-06-10
申请人： REGENERON PHARMACEUTICALS, INC. , ECONOMIDES, Aris, N. , VALENZUELA, David, M. , DAVIS, Samuel , YANCOPOULOS, George
发明人： ECONOMIDES, Aris, N. , VALENZUELA, David, M. , DAVIS, Samuel , YANCOPOULOS, George
IPC分类号： C12N15/00
CPC分类号： C12N15/85 , A01K67/0275 , A01K2217/05 , A01K2217/075 , A61D19/04 , C12N15/907 , C12N2800/30 , C12N2830/42 , C12N2840/44
摘要： Methods of creating mutations in genomic exons by inserting introns into the genomic exons via homologous recombination. Also, methods are provided for introducing modifications into genomic exons by inserting introns into the genomic exons via homologous recombination such that a mature mRNA transcript produced from a genomic region of the genome comprising the genomic exon does not contain the modification are provided. The methods provide for a rapid method for introducing mutations and/or modifications of any type into a mammalian cell genome.
摘要翻译：通过将内含子通过同源重组插入到基因组外显子中而在基因组外显子中产生突变的方法。此外，提供了通过将内含子通过同源重组插入到基因组外显子中而将修饰引入基因组外显子的方法，从而提供了从包含基因组外显子的基因组的基因组区域产生的成熟mRNA转录物不含修饰。所述方法提供了用于将任何类型的突变和/或修饰引入哺乳动物细胞基因组的快速方法。

10. 发明申请

WO2002098217A1 METHOD FOR TARGETING TRANSCRIPTIONALLY ACTIVE LOCI 审中-公开
标题翻译：用于定向转移活动位置的方法
公开(公告)号：WO2002098217A1
公开(公告)日：2002-12-12
申请号：PCT/US2002/017580
申请日：2002-06-05
申请人： REGENERON PHARMACEUTICALS, INC. , ECONOMIDES, Aris, N. , DECHIARA, Thomas, M. , YANCOPOULOS, George, D.
发明人： ECONOMIDES, Aris, N. , DECHIARA, Thomas, M. , YANCOPOULOS, George, D.
IPC分类号： A01K67/00
CPC分类号： C12N15/8509 , A01K2217/05 , A01K2217/075 , A01K2227/105 , A01K2267/03 , A01K2267/0393 , C12N15/907 , C12N2800/30 , C12N2830/00
摘要： The present invention is a method of targeting promoter-less selection cassettes into transcriptionally active loci. In particular, the invention is a method for targeting promoter-less selection cassettes into transcriptionally active loci in stem cells or other eukaryotic cells with much greater efficiency than previously observed with other methods, thus reducing or eliminating the need to screen for targeted cells. The invention also encompasses the DNA targeting vectors, the targeted cells, as well as non-human organisms, especially mice, created from the targeted cells.
摘要翻译：本发明是将无启动子选择盒靶向转录活性位点的方法。特别地，本发明是一种将促进剂选择盒靶向干细胞或其他真核细胞转录活性基因座的方法，其效率比先前用其他方法观察到的效率高得多，从而减少或消除了筛选靶细胞的需要。本发明还包括从靶细胞产生的DNA靶向载体，靶细胞以及非人生物，特别是小鼠。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式